Living Cell Technologies Limited (ASX:LCT) Insider Buys A$70,000.00 in Stock

Living Cell Technologies Limited (ASX:LCTGet Rating) insider Robert Willcocks bought 10,000,000 shares of Living Cell Technologies stock in a transaction dated Friday, June 3rd. The shares were acquired at an average cost of A$0.01 ($0.01) per share, with a total value of A$70,000.00 ($50,359.71).

The company has a current ratio of 11.80, a quick ratio of 11.80 and a debt-to-equity ratio of 10.03.

Living Cell Technologies Company Profile (Get Rating)

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Living Cell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Living Cell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.